TGF Beta1 Expression Correlates with Survival and Tumor Aggressiveness of Prostate Cancer
- 349 Downloads
Although biopsy Gleason score and clinical stage can be used to inform treatment decisions for prostate cancer, identifying molecular markers of tumor aggressiveness could lead to a more tailored approaches to therapy. In the present study, we investigated the association of transforming growth factor (TGF)-β1 levels and various markers of tumor aggressiveness and explore some potential mechanisms underlying the associations.
We used human and murine prostate cancer cell lines and their respective hormone resistance sub-lines, in vitro and in vivo to examine the changes in tumor aggressiveness, as well as the pathway responsible for these changes. Furthermore, 105 prostate cancer biopsy specimens were analyzed to correlate the level of TGF-β1 with the clinical characteristics of patients.
Our data revealed that activated TGF-β1 signaling resulted in more aggressive tumor growth and augmented the epithelial–mesenchymal transition. Activated IL-6 signaling was associated with TGF-β1 levels and the aggressive tumor features noted in TGF-β1-positive prostate cancers in vitro and in vivo. Furthermore, the TGF-β1 levels significantly correlated with Tregs accumulation in vivo. The clinical data indicated that TGF-β1 immunoreactivity had a moderate positive correlation with IL-6 staining, advanced clinical stage, higher Gleason score, and pretreatment PSA in patients with prostate cancer.
TGF-β1 levels are significantly associated with aggressive prostate features. In vitro and in vivo alternations of TGF-β1 expression impacts tumor invasiveness, tumor growth rate and recruitment of immunosuppressive Treg cells in the tumor microenvironment. TGF-β1 expression may represent a clinical useful biomarker to guide prostate cancer treatment decisions.
KeywordsProstate Cancer Prostate Cancer Cell Gleason Score Hormone Resistance Aggressive Prostate Cancer
The study was supported by National Science Council, Taiwan. Grant 101-2314-B-182-062-MY3.
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
- 1.Murray NP, Reyes E, Tapia P, et al. Redefining micrometastasis in prostate cancer: a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med. 2012;30:896–904.PubMedGoogle Scholar
- 2.National Comprehensive Cancer Network. Prostate Cancer (Version 1.2015). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 23 June 2015.
- 21.Hurwitz AA, Foster BA, Allison JP, et al. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2001;Chapter 20:Unit 20.5.Google Scholar